Ethyl diatrizoate is an ionic contrast agent used in medical imaging techniques such as X-ray, computed tomography (CT), and angiography. It is a derivative of diatrizoic acid and contains an iodine atom which gives it its radiopaque properties. This compound is typically administered intravenously and allows for the visualization of blood vessels, organs, and other structures during imaging. Its effects on the body are generally temporary and include a feeling of warmth, nausea, and flushing. Its importance lies in its ability to enhance the contrast between different tissues and organs, making it easier for healthcare professionals to diagnose and treat various medical conditions. The synthesis of ethyl diatrizoate involves several chemical reactions, starting with the synthesis of diatrizoic acid. It is studied extensively to understand its pharmacokinetics, pharmacodynamics, and potential side effects. The research on ethyl diatrizoate aims to improve its safety, efficacy, and optimize its use in various medical settings.'
| ID Source | ID |
|---|---|
| PubMed CID | 16567 |
| SCHEMBL ID | 332859 |
| MeSH ID | M0237062 |
| Synonym |
|---|
| ethyl diatrizoate |
| ethyl 3,5-diacetamido-2,4,6-triiodobenzoate |
| 2168-75-4 |
| win 05316 |
| 85kd8i5n2u , |
| win 8883 |
| benzoic acid, 3,5-bis(acetylamino)-2,4,6-triiodo-, ethyl ester |
| unii-85kd8i5n2u |
| benzoic acid, 3,5-diacetamido-2,4,6-triiodo-, ethyl ester |
| ethyl 3,5-bis(acetylamino)-2,4,6-triiodobenzoate |
| 3,5-diacetamido-2,4,6-triiodo-benzoic acid ethyl ester |
| win-8883 |
| diatrizoic acid, ethyl ester |
| diatrizoate ethyl |
| SCHEMBL332859 |
| DTXSID70176069 |
| ethyl-3,5-bis(acetylamino)-2,4,6-triiodobenzoate |
| Q27269652 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dose-response (0." | ( Percutaneous computed tomography lymphography in the rabbit by subcutaneously injected nanoparticulates. Bacon, ER; Cooper, ER; Gazelle, GS; Haley, PJ; McIntire, GL; Toner, JL; Wolf, GL, 1994) | 0.29 |
| " With the blood pool agent, similar contrast enhancement to the conventional agent was achieved with about 36% reduced dosage of iodine per body weight (mg I/kg)." | ( Comparison of liver perfusion parameters studied with conventional extravascular and experimental intravascular CT contrast agents. Häkkinen, AM; Halavaara, J; Kapanen, M, 2007) | 0.34 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.10) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||